Key points are not available for this paper at this time.
High prices for cancer drugs preclude independent comparative effectiveness trials that would seek to establish equally effective but cheaper alternatives — thereby protecting the market share of expensive drugs. How can we make progress toward conducting such trials?
Mailankody et al. (Wed,) studied this question.